iPTH is not a significant factor influencing the tacrolimus C/D ratio

Westphal, Florian; Jehn, U.; Görlich, Dennis; Reuter, Stefan

doi:10.1111/cts.13245

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Infection with S. aureus has adverse clinical outcomes including a greater degree of airway inflammation and lower lung function. [28][29][30][31] Given the importance of this pathogen in younger pwCF, prophylactic therapy followed by suppressive strategies following acquisition with narrow-spectrum anti-Staphylococcal therapies has been assessed in multiple contexts, [32][33][34][35] but its routine use is regionally dependent.…”

Section: Staphylococcus Aureusmentioning

confidence: 99%

Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future

Thornton

Parkins

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Progressive obstructive lung disease secondary to chronic airway infection, coupled with impaired host immunity, is the leading cause of morbidity and mortality in cystic fibrosis (CF). Classical pathogens found in the airways of persons with CF (pwCF) include Pseudomonas aeruginosa, Staphylococcus aureus, the Burkholderia cepacia complex, Achromobacter species, and Haemophilus influenzae. While traditional respiratory-tract surveillance culturing has focused on this limited range of pathogens, the use of both comprehensive culture and culture-independent molecular approaches have demonstrated complex highly personalized microbial communities. Loss of bacterial community diversity and richness, counteracted with relative increases in dominant taxa by traditional CF pathogens such as Burkholderia or Pseudomonas, have long been considered the hallmark of disease progression. Acquisition of these classic pathogens is viewed as a harbinger of advanced disease and postulated to be driven in part by recurrent and frequent antibiotic exposure driven by frequent acute pulmonary exacerbations. Recently, CF transmembrane conductance regulator (CFTR) modulators, small molecules designed to potentiate or restore diminished protein levels/function, have been successfully developed and have profoundly influenced disease course. Despite the multitude of clinical benefits, structural lung damage and consequent chronic airway infection persist in pwCF. In this article, we review the microbial epidemiology of pwCF, focus on our evolving understanding of these infections in the era of modulators, and identify future challenges in infection surveillance and clinical management.

show abstract